Equities research analysts at StockNews.com began coverage on shares of Zevra Therapeutics (NASDAQ:KMPH – Get Rating) in a research report issued on Sunday. The firm set a "hold" rating on the specialty pharmaceutical company's stock.

Zevra Therapeutics Stock Performance

The business has a 50-day moving average price of $5.46 and a 200 day moving average price of $5.38. Zevra Therapeutics has a 52 week low of $4.00 and a 52 week high of $6.92. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.10 and a current ratio of 10.10.

Insider Transactions at Zevra Therapeutics

In other news, CEO Richard W. Pascoe bought 9,500 shares of the company's stock in a transaction dated Friday, January 13th. The shares were purchased at an average price of $5.44 per share, for a total transaction of $51,680.00. Following the completion of the purchase, the chief executive officer now owns 19,973 shares in the company, valued at approximately $108,653.12. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KMPH. UBS Group AG bought a new position in Zevra Therapeutics during the second quarter valued at approximately $26,000. Verition Fund Management LLC bought a new position in Zevra Therapeutics during the fourth quarter valued at approximately $46,000. Invesco Ltd. bought a new position in Zevra Therapeutics during the first quarter valued at approximately $51,000. Kingsview Wealth Management LLC bought a new position in Zevra Therapeutics during the second quarter valued at approximately $54,000. Finally, HRT Financial LP bought a new position in Zevra Therapeutics during the fourth quarter valued at approximately $66,000. Institutional investors own 19.39% of the company's stock.

About Zevra Therapeutics

(Get Rating)

KemPharm, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.

See Also

• Get a free copy of the StockNews.com research report on Zevra Therapeutics (KMPH)
• MarketBeat Week in Review – 3/27 – 3/31
• What is a Gold IRA, and is it a Viable Investment?
• Is Braze Inc Ready To Rocket Higher?
• Mullen Automotive Makes Deliveries; Short-Squeeze Possible
• Can Frontline Maintain This Momentum?

Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.